Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer
NCT04243616Phase 2Active, not recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Mar 2020
- Primary completion
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in breast cancer, sponsored by Medical College of Wisconsin. Primary endpoint: Pathological Complete Response at 27 weeks. Started Mar 2020; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04243616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04243616.